A pharmaceutical company brought on a CRA consultant to estimate economic damages arising from alleged infringement and at-risk launch of a patented oral antihyperglycemic drug used in the management of type 2 diabetes. The alleged economic damages were estimated according to appropriateness and, if so, quantum of lost profits, price erosion, and reasonable royalty elements.
Overview of IP litigation in the US involving Chinese companies
This underscores China’s growing commitment to address intellectual property (IP) disputes with foreign entities. While litigators and companies are evaluating...